Imetelstat
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Rytelo |
| Other names | GRN163L |
| AHFS/Drugs.com | Rytelo |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C148H211N68O53P13S13 |
| Molar mass | 4610.18 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia.[1] Imetelstat is an oligonucleotide telomerase inhibitor.[1][2]
The most common adverse reactions include decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.[3]
Imetelstat was approved for medical use in the United States in June 2024.[3][4]
Medical uses
[edit]Imetelstat is indicated for the treatment of adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.[1][3]
History
[edit]Imetelstat is the first telomerase inhibitor to enter clinical trials.[5]
Chemically, imetelstat is a synthetic conjugate consisting of three parts: GRN163, a thio phosphoramide oligonucleotide, and a palmitoyl lipid group.[5] GRN163 is the pharmacological component with telomerase inhibition based on experiments with poly-G oligonucleotides first conducted at the University of Nebraska Medical Center under contract with Lynx Therapeutics.[6] The palmitic acid moiety is conjugated via a phosphothioate linkage to the backbone of the antisense oligonucleotide.[medical citation needed] Telomere shortening and lower cell viability are observed after inhibition of telomerase activity in vitro.[medical citation needed] IC50 values ranged from 50 to 200nM for 10 different pancreatic cell lines.[7]
The efficacy of imetelstat was evaluated in IMerge (NCT02598661), a randomized (2:1), double-blind, placebo-controlled multicenter trial in 178 participants with myelodysplastic syndromes.[3] Participants received an intravenous infusion of imetelstat 7.1 mg/kg or placebo in 28-day treatment cycles until disease progression or unacceptable toxicity.[3] Randomization was stratified by prior red blood cell transfusion burden and by International Prognostic Scoring System (IPSS) risk group.[3] All participants received supportive care, which included red blood cell transfusions.[3]
Society and culture
[edit]Legal status
[edit]Imetelstat was approved for medical use in the United States in June 2024.[3] The FDA granted the application for imetelstat orphan drug designation.[3][8][9]
Names
[edit]Imetelstat is the international nonproprietary name.[10]
References
[edit]- ^ a b c d "Archived copy" (PDF). Archived (PDF) from the original on 7 June 2024. Retrieved 7 June 2024.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Burchett KM, Yan Y, Ouellette MM (2014). "Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells". PLOS ONE. 9 (1): e85155. Bibcode:2014PLoSO...985155B. doi:10.1371/journal.pone.0085155. PMC 3883701. PMID 24409321.
- ^ a b c d e f g h i "FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia". U.S. Food and Drug Administration (FDA). 6 June 2024. Archived from the original on 7 June 2024. Retrieved 7 June 2024.
This article incorporates text from this source, which is in the public domain.
- ^ "Geron Announces FDA Approval of Rytelo (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia" (Press release). Geron. 7 June 2024. Archived from the original on 7 June 2024. Retrieved 7 June 2024 – via Business Wire.
- ^ a b Relitti N, Saraswati AP, Federico S, Khan T, Brindisi M, Zisterer D, et al. (2020). "Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials". Current Topics in Medicinal Chemistry. 20 (6): 433–457. doi:10.2174/1568026620666200102104930. PMID 31894749. S2CID 209543655.
- ^ Mata JE, Joshi SS, Palen B, Pirruccello SJ, et al. (1997). "A Hexameric Phosphorothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitt's Lymphoma Cellsin Vitro and in Vivo". Toxicology and Applied Pharmacology. 144 (6): 189–197. Bibcode:1997ToxAP.144..189M. doi:10.1006/taap.1997.8103. PMID 9169084.
- ^ Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. (November 2005). "Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma". Hepatology. 42 (5): 1127–36. doi:10.1002/hep.20822. PMID 16114043.
- ^ "Imetelstat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 7 June 2024. Retrieved 7 June 2024.
- ^ "Imetelstat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 7 June 2024. Retrieved 7 June 2024.
- ^ World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 63". WHO Drug Information. 24 (1). hdl:10665/74530.
External links
[edit]- "Imetelstat (Code C49084)". NCI Thesaurus.
- "Imetelstat Sodium (Code C84511)". NCI Thesaurus.</ref>
- MeSH 67519562
